Trial Profile
An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 06 Mar 2018
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- 29 Feb 2016 Status changed from recruiting to withdrawn prior to enrolment as per the ClinicalTrials.gov record.
- 14 Oct 2014 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017, as reported by Clinicaltrials.gov record,
- 14 Oct 2014 Status changed from not yet recruiting to recruiting, as reported by Clinicaltrials.gov record,